ArticleHeliyon2025

A non-randomised open-label exploratory 'window of opportunity' study of TG02 treatment in patients with locally advanced primary and recurrent

Sara Roth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.